Dr. Louis Lacombe is a urologist-oncologist and clinical researcher at the CHU de Québec, and more specifically at L’Hôtel-Dieu de Québec.
Dr. Lacombe completed his medical training in Sherbrooke in 1988 and then completed a specialization in Urology at Laval University in 1993. Subsequently, Dr. Lacombe traveled to New York at the Memorial Sloan-Kettering Cancer Center associated with Cornell University to perform a subspecialisation in uro-oncology. This subspecialisation ended in 1996.
Following this subspecialisation, Dr. Lacombe joined the Urology Department of the CHU de Québec in July 1996. As a urologist, Dr. Lacombe specializes in complex surgeries associated with prostate, kidney, testicular and bladder cancer. He also collaborates in kidney transplant surgery.
Research at the Experimental Uro-oncology Laboratory aims to improve the diagnosis, prognosis, and therapy of prostate, bladder, and kidney cancers, and thus cover many aspects of research, from basic research to applied research. His interest is mainly focused on bladder cancer.
Dr. Lacombe is also actively involved in clinical research by conducting numerous Phase I, Phase II or Phase III clinical trials to test new drugs or therapies. He has been the principal investigator or co-investigator in more than 120 studies since the beginning of his career.
He has published more than 110 scientific papers and more than 250 scientific abstracts, and has presented at many international conferences.
Throughout his career, he has been awarded the FRQS Junior I and II Clinician Fellowship. He is currently a full professor in the Department of Surgery, and since 2016 he is the Director of the University Department of Surgery at the School of Medicine at Laval University.
1401, 18e rue
Canada G1J 1Z4
- Brisson, HervéEmployeeL'Hôtel-Dieu de Québec+1 418-525-4444, extension 16849+1 email@example.com
Canada G1R 2J6
- Gagné, ChristineEmployeeHôpital de l'Enfant-Jésus+1 418-525-4444, extension firstname.lastname@example.org
1401, 18e rue
Canada G1J 1Z4
- Verret, NadiaEmployee+1 418-525-4444, extension email@example.com
Preoperative Circulating 11-Oxygenated Androgens Are Associated With Metastasis-free Survival in Localized Prostate CancerJournal Article
J Urol, 2022.
UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathwaysJournal Article
Cancer Lett, 553 , 2022.
Extensive metabolic consequences of human glycosyltransferase gene knockouts in prostate cancerJournal Article
Br J Cancer, 2022.
Analysis of sex-based differences to Bacillus Calmette-Guérin for non-muscle invasive bladder cancerJournal Article
Urol Oncol, 40 (12), 2022.
Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen LevelJournal Article
J Urol, 208 (6), 2022.
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trialJournal Article
J Immunother Cancer, 10 (8), 2022.
Uridine Diphosphate Glucuronosyl Transferase 2B28 (UGT2B28) Promotes Tumor Progression and Is Elevated in African American Prostate Cancer PatientsJournal Article
Cells, 11 (15), 2022.
Perception and satisfaction of patients after telemedicine urology consultations: A matched analysis with physicians' perspectiveJournal Article
Can Urol Assoc J, 16 (10), 2022.
Multiple metabolic pathways fuel the truncated tricarboxylic acid cycle of the prostate to sustain constant citrate production and secretionJournal Article
Mol Metab, 62 , 2022.
Sex steroid modulation of macrophages within the prostate tumor microenvironmentJournal Article
Am J Clin Exp Urol, 10 (2), 2022.
- Aberrant UGT2B28 androgen inactivation pathway predicts prostate cancer progression, from 2021-09-01 to 2023-08-31
- Soutien à la recherche, from 2017-07-01 to 2024-06-30
- Targeting sex steroids to improve the response to bladder cancer immunotherapy, from 2021-10-01 to 2026-09-30
Recently finished projects
- Interaction between environment, diet, physical activities, and sexual habits, in the risk of prostate cancer. Validation of biomarkers to personnalize preventive interventions., from 2012-10-01 to 2021-12-31
- The Contribution of Non-Classical 11-oxy Androgens to Prostate Cancer Progression, from 2019-04-01 to 2022-03-30